Mucormycoses - 19/02/16
, Dimitrios P. Kontoyiannis, MD, ScD bRésumé |
Life-threatening infections from virulent, angioinvasive molds of the order Mucorales are being recognized with increasing frequency in immunosuppressed hosts. Advances in the understanding of pathogenesis, early diagnosis, and the recent availability of active, nontoxic drugs have improved the prospects for effective control and even cure of this devastating infection. However, rates of delayed diagnosis and mortality are still high, partially because of the low yield and complexity of culture-based and molecular diagnostic methods. Therefore, there is an urgent need for novel diagnostic modalities and effective therapeutic approaches.
Le texte complet de cet article est disponible en PDF.Keywords : Amphotericin, Antifungal, Diabetes, Hematopoietic stem cell transplantation, Immunocompromised, Ketoacidosis, Isavuconazole, Leukemia
Plan
| Disclosures: D.P. Kontoyiannis has received research support and honoraria from Astellas US, Pfizer, Gilead, and Merck & Co., Inc. D. Farmakiotis has nothing to disclose. |
Vol 30 - N° 1
P. 143-163 - mars 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
